TrialNature medicine2026

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Jennifer M Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.